TITLE

Review: Rofecoxib increases renal events and arrhythmia, but a COX-2-inhibitor class effect does not exist

AUTHOR(S)
Molony, Donald A.
PUB. DATE
January 2007
SOURCE
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p25
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a research study regarding the risk factors for renal and arrhythmia events in patients using cyclooxygenase-2 (COX-2) inhibitors. The study was conducted by researcher J. Zhang, and published in the "Journal of the American Medical Association." Use of rofecoxib increases risks for renal events and arrhythmia. Evidence of increased risk associated with other COX-2 inhibitors is not supported, indicating no overall class effect.
ACCESSION #
23847355

 

Related Articles

  • New meta-analyses evaluate effect of COX-2 inhibitors on renal and CV events, including arrhythmia.  // Formulary;Nov2006, Vol. 41 Issue 11, p558 

    The article presents information on the two new meta-analyses that evaluate the adverse effects of cyclooxygenase-2 (COX-2) inhibitors on renal and cardiovascular events including arrhythmia. A population-based study was conducted by the researchers to know the effect of COX-2. One of the...

  • Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events. Jingjing Zhang; Ding, Eric L.; Yiqing Song // JAMA: Journal of the American Medical Association;10/4/2006, Vol. 296 Issue 13, p1619 

    Context Adverse effects of selective cyclooxygenase 2 (COX-2) inhibitors on renal events and arrhythmia have been controversial, with suggestions of a class effect. Objective To quantitatively evaluate adverse risks of renal events (renal dysfunction, hypertension, and peripheral edema) and...

  • Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition Klein, Thomas; Eltze, Manfrid; Grebe, Thomas; Hatzelmann, Armin; Kömhoff, Martin // Cardiovascular Research;Jul2007, Vol. 75 Issue 2, p390 

    Abstract: Objective : Celecoxib carries a smaller cardiovascular risk for myocardial infarction and hypertension than other cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drugs NSAIDs (“coxibs”) and may ameliorate endothelial dysfunction. We aimed to determine...

  • The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Kawashima, Masayuki; Fujikawa, Yosuke; Itonaga, Ichiro; Takita, Chikahiro; Tsumura, Hiroshi // Modern Rheumatology (Springer Science & Business Media B.V.);Apr2009, Vol. 19 Issue 2, p192 

    The inducible prostaglandin synthesis enzyme, cyclooxygenase-2 (COX-2), is involved in bone resorption and osteoclastogenesis, and acts indirectly through prostaglandin E2 (PG E2) produced by osteoblastic cells. This study was undertaken to investigate whether celecoxib (a selective COX-2...

  • COX-2 inhibitors: 'risk-inducing' effect at higher doses.  // Reactions Weekly;10/14/2006, Issue 1123, p5 

    The article discusses research being done on the risk-reducing effect of cyclooxygenase-2 inhibitors at higher doses. According to researchers from Australia, the overall risk of acute coronary syndromes (ACS) does not appear to increase with the use of celecoxib or rofecoxib, but the odds of...

  • Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice. Dhir, A.; Kulkarni, S. K. // Inflammopharmacology;Dec2006, Vol. 14 Issue 5/6, p222 

    Numerous studies have implicated prostaglandins as potential modulators in seizure activity. The objective of the present study was to elucidate the effect of rofecoxib (selective COX-2 inhibitor) alone or in combination with newer antiepileptic drug tiagabine (γ-amino acid reuptake...

  • Rofecoxib potentiates the anticonvulsant effect of topiramate. Dhir, A.; Akula, K. K.; Kulkarni, S. K. // Inflammopharmacology;Apr2008, Vol. 16 Issue 2, p83 

    The present study examines the effect of rofecoxib in combination with topiramate (a newer antiepileptic) against PTZ (80 mg/kg, i. p.)-induced chemoconvulsions in mice. Pretreatment with rofecoxib (1.0 and 5.0 mg/kg., i. p.) or topiramate (50 and 100 mg/kg., i. p.) dose dependently protected...

  • Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data. Edwards, Jayne E.; Moore, R. Andrew; McQuay, Henry J. // BMC Women's Health;2004, Vol. 4, p5 

    Background: Individual patient meta-analysis to determine the analgesic efficacy and adverse effects of single-dose rofecoxib in primary dysmenorrhoea. Methods: Individual patient information was available from three randomised, double blind, placebo and active controlled trials of rofecoxib....

  • Anti-inflammatory Options: VIOXX and other Selective COX-2 Inhibitors v Natural Agents. Brady, David M.; Paul, Cristiana // Nutritional Perspectives: Journal of the Council on Nutrition;Apr2009, Vol. 32 Issue 2, p33 

    The article provides an answer to a question on how Vioxx and other selective cyclooxygenase-2 (COX-2) inhibiting anti-inflammatory medications change the recommendations on the use of anti-inflammatory agents.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics